36446 Federal Register / Vol. 65, No. 111 / Thursday, June 8, 2000 / Notices

Trans No. Acquiring Acquired Entities

20003061 ..... Westvaco Corporation ............................. IMPAC Group, Inc ................................... IMPAC Group, Inc.

20003064 ..... Bill Gross’ Idealab! ................................... PayMyBills.com, Inc ................................. PayMyBills.com, Inc.

20003070 ..... Safeway, Inc ............................................ GroceryWorks.com, Inc ........................... GroceryWorks.com, Inc.

20003073 ..... Novell, Inc ................................................ CMGI, Inc ................................................. CMGion, Inc.

20003075 ..... Robert Andy ............................................. Carl M. and Marie T. Bouckaert .............. Epsilon Products Company.

Transactions Granted Early Termination—05/18/2000

20002984 ..... Interdean Group Limited .......................... Interconex, Inc ......................................... Interconex, Inc.

20003020 ..... Peninsular and Oriental Steam Navigation Company.Texas Freezer Company, Inc .................. Texas Freezer Company, Inc.

20003048 ..... Telia A.B .................................................. Apex Global Information Services, Inc .... Apex Global Information Services, Inc.

20003055 ..... World Access, Inc .................................... Joseph D. Fail .......................................... Prime TEC International, Inc.

20003069 ..... Informa Group plc .................................... The BISYS Group, Inc ............................. BISYS Research Services, Inc.

20003080 ..... Galen Holdings PLC ................................ Duke University ........................................ Applied Clinical Concepts, Inc.

Duke Clinical Research Institute.

20003081 ..... Professor Kurt Jenny ............................... Dr. Helmut List ......................................... AVL Medical Instruments AG.

20003083 ..... ABRY Broadcast Partners III, L.P ........... Kelso Investment Associates V, L.P ....... Cygnus Business Media Holdings, Inc.

20003084 ..... TCV III (Q), L.P ........................................ eLoyalty Corporation ................................ eLoyalty Corporation.

20003086 ..... Nortrax, Inc .............................................. Donald Neidetcher ................................... METCO.

20003087 ..... Nortrax, Inc .............................................. Roger N. Michaud .................................... METCO.

20003089 ..... Nortrax, Inc .............................................. K.C. Canary-Clifton Park, Inc .................. K.C. Canary-Clifton Park, Inc.

20003090 ..... CSR Limited ............................................. Leppert Concrete Products, LLC ............. Leppert Concrete Products, LLC.

20003091 ..... St. Ives plc ............................................... Joseph H. Weiss ...................................... Packard Press, Inc.

20003092 ..... VS&A Communications Partners II, L.P .. Third Millennium Communications, Inc .... Third Millennium Communications, Inc.

20003095 ..... REMEC, Inc ............................................. SkyOnline, Inc .......................................... SkyOnline, Inc.

20003100 ..... MGC Communications, Inc ...................... Primary Network Holdings, Inc ................ Primary Network Holdings, Inc.

20003109 ..... Heywood Williams Group PLC ................ Fastec Industrial Corp ............................. Fastec Industrial Corp.

20003119 ..... Hicks, Muse, Tate & Furst Equity Fund

III, L.P.

Top Line Electronics Corporation ............ Top Line Electronics Corporation.

20003120 ..... Illinois PCS, LLC ...................................... Sprint Corporation .................................... Sprint Spectrum L.P., Sprint Spectrum

Equipment Co., L.P.

Transactions Granted Early Termination—05/19/2000

20001681 ..... Healtheon/WebMD Corporation ............... Quintiles Transnational Corp. .................. ENVOY Corporation.

20001682 ..... Quintiles Transnational Corp ................... Healtheon/WebMD Corporation ............... Healtheon/WebMD Corporation.

20003050 ..... ING Groep N.V ........................................ Acsys, Inc ................................................ Acsys, Inc.

For Further Information Contact:

Sandra M. Peay or Parcellena P.

Fielding, Contact Representatives,

Federal Trade Commission, Premerger

Notification Office, Bureau of

Competition, Room 303, Washington,

DC 20580, (202) 326–3100.

By direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 00–14450 Filed 6–7–00; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 00127]

Developing a Model System for the

Collection, Analysis, and

Dissemination of Data on Genetic

Tests; Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2000

funds for a cooperative agreement

program for Developing a Model System

for the Collection, Analysis, and

Dissemination of Data on Genetic Tests.

CDC is committed to achieving the

health promotion and disease

prevention objectives of ‘‘Healthy

People 2010,’’ a national activity to

reduce morbidity and mortality and

improve the quality of life. This

announcement is related to the focus

area of Public Health Infrastructure. For

the conference copy of ‘‘Healthy People

2010,’’ visit the Internet site: <http://

www.health.gov/healthypeople>.

The purpose of the program is to

develop and evaluate a model system to

assess the availability, quality, and

usefulness of existing data on DNAbased genetic tests and testing

algorithms. These data are needed to

facilitate the appropriate transition of

genetic tests from investigational

settings to clinical and public health

practice. By identifying data gaps and

needs, this project can influence the

way that genetic testing data are

collected and analyzed in the future.

B. Eligible Applicants

Applications may be submitted by

public and private nonprofit

organizations and by governments and

their agencies; that is, universities,

colleges, research institutions, hospitals,

other public and private nonprofit

organizations, State and local

governments or their bona fide agents,

and federally recognized Indian tribal

governments, Indian tribes, or Indian

tribal organizations.

Note: Public Law 104–65 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.

C. Availability of Funds

Approximately $200,000 is available

in FY 2000 to fund one award. It is

expected that the award will begin on or

about September 30, 2000, and will be

made for a 12-month budget period

within a project period of up to 3 years.

Funding estimates may change.

Continuation awards within an

approved project period will be made

Federal Register / Vol. 65, No. 111 / Thursday, June 8, 2000 / Notices 36447

on the basis of satisfactory progress as

evidenced by required reports and the

availability of funds.

Use of Funds

Funds may not be used to support

genetic testing or generate new genetic

test results.

D. Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for the activities

under 1. (Recipient Activities), and CDC

will be responsible for the activities

listed under 2. (CDC Activities). Please

see Addendum II (in the application kit)

for important additional information.

1. Recipient Activities

a. Develop a comprehensive plan

including time-phased and measurable

objectives and proposed methods for

implementing and evaluating the

project.

b. Identify all applicable laws and

develop procedures to protect

confidentiality and maintain the

anonymity of all test results.

c. Using experts, identify three DNAbased tests to guide in the finding,

collection, and analysis of relevant data

(published and unpublished).

d. Evaluate the availability, quality,

and usefulness of data, identify data

gaps and needs, and design simple and

common data formats that support

pooled analysis and comparison among

studies.

e. Determine the core data elements

needed (test- and population-specific)

and assess the analytic validity, clinical

validity and clinical utility of the

studied genetic tests.

f. Develop and test a model system for

actively collecting, analyzing, and

disseminating aggregate data.

g. Evaluate the model system and

summarize its strengths and limitations

in transitioning genetic tests to clinical

and public health practice and describe

possible future enhancements.

h. Publish and disseminate results.

2. CDC Activities

a. Provide technical assistance and

oversight of all project activities.

b. Assist in identifying DNA test

experts to participate in collaborative

analysis.

c. Provide scientific guidance in

establishing selection criteria for the

genetic tests to be studied.

d. Present project findings to relevant

agencies and the Secretary’s Advisory

Committee on Genetic Testing.

e. Provide staff expertise in the

implementation of the model system to

be developed.

E. Application Content

Use the information in the Program

Requirements, Other Requirements, and

Evaluation Criteria sections to develop

the application content. Your

application will be evaluated on the

criteria listed, so it is important to

follow them in laying out your program

plan. The narrative should be no more

than 25 single-spaced pages, printed on

one side, with one inch margins, and

unreduced font. The application must

be submitted unstapled and unbound.

F. Submission and Deadline

Submit the original and five copies of

PHS–398 (OMB Number 0925–0001)

(adhere to the instructions on the Errata

Instruction Sheet for PHS 398). Forms

are available in the application kit.

On or before August 4, 2000 submit

the application to the Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

Deadline: Applications shall be

considered as meeting the deadline if

they are either:

(a) Received on or before the deadline

date; or

(b) Sent on or before the deadline date

and received in time for submission to

the Objective Review Panel. (Applicants

must request a legibly dated U.S. Postal

Service postmark or obtain a legibly

dated receipt from a commercial carrier

or U.S. Postal Service. Private metered

postmarks shall not be acceptable as

proof of timely mailing.)

Late Applications: Applications

which do not meet the criteria in (a) or

(b) above are considered late

applications, will not be considered,

and will be returned to the applicant.

G. Evaluation Criteria

Each application will be evaluated

individually against the following

criteria by an independent review group

appointed by CDC.

1. Background (15 Points)

The extent to which the applicant

demonstrates an understanding of the

program objectives by including a

critical review of existing approaches to

assessing the performance of DNA-based

tests in public health applications.

2. Qualifications and Experience (25

Points)

The extent to which the applicant:

a. Identifies a principal investigator

with demonstrated ability to carry out

the proposed project,

b. Documents access to the necessary

administrative, clinical, genetic,

epidemiologic, laboratory, data

management and statistical talent

needed to carry out the project, and

c. Describes a project team that is

experienced in collecting, organizing,

analyzing, and interpreting DNA-based

data on different conditions.

3. Plan and Objectives (20 Points)

a. The extent to which the applicant

presents a well-defined project plan,

including time-phased, measurable

objectives.

b. The extent to which the applicant

includes letters of support indicating

the nature and extent of collaboration of

key experts.

4. Methods (25 Points)

The extent to which the applicant

describes detailed methods for

implementing the project, including:

a. Identifying, recruiting, and

collaborating with key experts,

b. Ensuring data anonymity and

protecting confidentiality,

c. Identify available data for three

DNA-based tests, identifying data gaps,

and developing common data formats,

d. Determining core data elements

and performing critical analysis,

e. Developing and testing a system for

organizing and updating aggregate data

sets, and disseminating results.

5. Evaluation (15 Points)

The extent to which the applicant:

a. Describes a plan to evaluate the

ability of the model to collect, analyze,

and disseminate data on genetic tests to

facilitate their use in clinical and public

health practice, and

b. Provides an evaluation plan that

allows measurement of progress toward

the achievement of the stated objectives.

6. Budget (Not Scored)

The extent to which the budget is

reasonable, clearly justified, and

consistent with the intended use of

grant funds. All budget categories

should be itemized.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two

copies of:

1. Annual progress reports;

2. Financial status report, no more

than 90 days after the end of the budget

period; and

3. Final financial and performance

reports, no more than 90 days after the

end of the project period.

Send all reports to the Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

The following additional

requirements are applicable to this

36448 Federal Register / Vol. 65, No. 111 / Thursday, June 8, 2000 / Notices

program. For a complete description of

each, see Addendum I in the application

kit.

AR–7 Executive Order 12372 Review

AR–9 Paperwork Reduction Act

Requirements

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

sections 301 and 317 of the Public

Health Service Act, [42 U.S.C. sections

241 and 247b, as amended. The Catalog

of Federal Domestic Assistance number

is 93.283.

J. Where To Obtain Additional

Information

This and other CDC announcements

may be downloaded through the CDC

Home Page on the Internet at <http://

www.cdc.gov> (click on Funding).

Please refer to Program Announcement

Number 00127 when requesting

information. To receive additional

written information and to request an

application kit, call 1–888-GRANTS4

(1–888 472–6874). You will be asked to

leave your name and address and will

be instructed to identify the

announcement number of interest.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from: Mattie

B. Jackson, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention, E–

13, Room 3000, 2920 Brandywine Road,

Atlanta, GA 30341–4146, Telephone

number: 770–488–2718, Email address:

mij3@cdc.gov

For program technical assistance,

contact: Marta Gwinn, MD, MPH, Senior

Medical Epidemiologist, Office of

Genetics and Disease Prevention,

National Center for Environmental

Health Centers for Disease Control and

Prevention, K–28, 4770 Buford

Highway, NE, Atlanta, GA 30341–3724,

Telephone number: 770–488–3235,

Email address: mlg1@cdc.gov

Dated: June 2, 2000.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Conrol and Prevention

(CDC).

[FR Doc. 00–14424 Filed 6–7–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement Number 00141]

Notice of Availability of Funds;

Surveillance of Intimate Partner

Violence (IPV)

A. Purpose

The Centers for Disease Control and

Prevention (CDC), announces the

availability of fiscal year (FY) 2000

funds for a cooperative agreement

program for Surveillance of Intimate

Partner Violence (IPV). The purpose(s)

of the program announcement are (1) to

improve state injury surveillance

capacity through the implementation of

the Consensus Recommendations For

Injury Surveillance In State Health

Departments, September 1999 Report,

for a copy of this report, visit the

Internet site: (http://

www.injuryprevention.org/stipda/spubs) and (2) to support the integration

of population-based IPV surveillance

systems into existing injury surveillance

systems that will help determine the

magnitude of IPV in population

subgroups, and continued revision and

testing of uniform definitions and

recommended data elements. This

program addresses ‘‘Healthy People

2010,’’ a national activity to reduce

morbidity and mortality and improve

health. This announcement is related to

the focus area of Injury and Violence

Prevention. For the conference copy of

‘‘Healthy People 2010’’, visit the

Internet site: http://www.health.gov/

healthypeople.

B. Eligible Applicants

Assistance will be provided only to

the official public health departments of

States or their bona fide agents,

including the District of Columbia, the

Commonwealth of Puerto Rico, the

Virgin Islands, the Commonwealth of

the Northern Mariana Islands, American

Samoa, Guam, federally recognized

Indian tribal governments, the

Federated States of Micronesia, the

Republic of the Marshall Islands, and

the Republic of Palau. States previously

funded under announcement number

94483 ‘‘State Injury Prevention

Programs’’ are eligible to apply

(Massachusetts, Michigan and Rhode

Island). States previously funded under

announcement number 99134 ‘‘State

Injury Prevention Programs’’ are not

eligible to apply (Kentucky and

Oklahoma).

Note: Public Law 104–65 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 which

engages in lobbying activities shall not be

eligible to receive Federal funds constituting

an award, grant cooperative agreement

contract, loan, or any other form.

C. Availability of Funds

Approximately $1.2 million is

available to fund up to four awards. It

is expected that the average award will

be $300,000. It is expected that the

awards will begin on or about

September 30, 2000 and will be made

for a 12-month budget period within a

project period of up to five years.

Funding estimates may change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress, as

evidenced by required reports, and the

availability of funds.

D. Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for the activities

under (1) Recipient Activities, and CDC

will be responsible for the activities

listed under (2) CDC Activities.

1. Recipient Activities

a. Enhance existing injury

surveillance activities to support

Intimate Partner Violence (IPV)

surveillance to identify victims and

occurrences of IPV, including data

describing the magnitude of the problem

and the extent of injuries (i.e., who is

affected, areas and persons at greatest

risk, and the type and source of the

information used).

b. Enhance an existing injury

surveillance system, capable of linking

with one or more health-related data

sources to determine intimate partner

violence incidence and prevalence in

the targeted area (e.g., linkage of

emergency department injury

surveillance data or hospital discharge

data with health-care based IPV

surveillance data).

c. Enhance the capacity for general

injury surveillance by incorporating the

IPV surveillance system into other

existing injury surveillance systems.

d. Using the Uniform Definitions for

IPV Surveillance, assess the feasibility

of enhancing existing injury

surveillance and integrating a subset of

the fifty recommended data elements:

Uniform Definitions and Recommended

Data Elements, 1999; http://

www.cdc.gov/ncipc/pub-res/

intimate.html into an existing healthcare related injury surveillance system.

Explain decisions made in selecting the

subset of 50 data elements.